The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation

Abstract

Cord blood transplantation is being used with increasing frequency for patients with high-risk hematologic malignancies. Myeloablative preparative regimens provide antitumor efficacy and facilitate engraftment but are associated with higher morbidity and nonrelapse mortality rates than nonablative regimens. We evaluated 3 sequential myeloablative regimens in the cord blood transplant setting. Regimen 1 (melphalan, fludarabine, and thiotepa) produced prompt engraftment and minimal engraftment failure but was associated with a high nonrelapse mortality rate. Regimen 2 (busulfan and fludarabine) was very well tolerated but was associated with a high rate of engraftment failure and relapse. Regimen 3 (busulfan, clofarabine, fludarabine, and low-dose total body irradiation given 9 days after the chemotherapy) was associated with a low rate of engraftment failure but was logistically difficult to administer. Finally, regimen 3 that included the total body irradiation given immediately after the chemotherapy was well tolerated, with prompt engraftment and tumor control. This latter regimen appears to be effective in preliminary studies and warrants further evaluation.

Keywords: Conditioning regimen; Hematologic malignancies; Stem cell transplant; Total body irradiation; Treatment related mortality.

Figure 1

(a–b): Kaplan-Meyer estimates of overall survival (OS) (a) and non-relapse mortality (NRM) (b) for the indicated cohort. Symbols indicate censoring (death or progression).

Figure 2

White blood cell (WBC) count per microliters of peripheral blood before and after treatment/stem cell infusion for regimens 1 to 3. Average of at least 5 patients per group + standard deviation is shown. Abbreviations: Mel=melphalan; Flu= fludarabine; Thio= thiotepa; CBT: cord blood transplant; Bu= busulfan; Clo=clofarabine; TBI= total body irradiation; CT= chemotherapy.